London (PRWEB UK) 21 September 2012
Microbiological contamination of products and processes in a lab and manufacturing environment continues to be a major problem to the Pharmaceutical and Biotechnological industries and its regulators. The potential impact of such contamination can be enormous, and does not only create health and safety problems but can also cost companies millions in lost product revenue.
Regulators will endeavour to ensure that the safety of the health care consumer is never compromised. Aseptic processing attracts a high level of regulatory scrutiny due to the risks associated with this type of manufacturing and its potential adverse effect on the health care consumer
SMi’s Pharmaceutical Microbiology conference will aim to provide an expert and highly accredited speaker line up including 13 pharma speakers who will focus on the latest developments and procedures used in the identification and prevention of contaminating agents, updates on new rules and regulations and the challenges facing the Pharmaceutical Microbiology industry. Attending will enable you to: